Media headlines about Summit Therapeutics (NASDAQ:SMMT) have been trending somewhat positive on Saturday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Summit Therapeutics earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.0532410057126 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
- Summit Therapeutics (SMMT) Upgraded by Zacks Investment Research to “Strong-Buy” (americanbankingnews.com)
- Summit Therapeutics to Present at the Biotech Showcase – GlobeNewswire (press release) (globenewswire.com)
- SunTrust Banks Comments on Summit Therapeutics PLC’s FY2018 Earnings (SMMT) (americanbankingnews.com)
- Summit Therapeutics (SMMT) Upgraded to Hold by Zacks Investment Research (americanbankingnews.com)
Summit Therapeutics (NASDAQ SMMT) opened at $12.68 on Friday. The firm has a market cap of $182.88 and a P/E ratio of -110.80. Summit Therapeutics has a 1 year low of $8.80 and a 1 year high of $16.86.
Several equities analysts have commented on the stock. Zacks Investment Research raised shares of Summit Therapeutics from a “hold” rating to a “strong-buy” rating and set a $14.00 target price on the stock in a research note on Friday. HC Wainwright set a $16.00 target price on shares of Summit Therapeutics and gave the company a “buy” rating in a research note on Wednesday, December 27th. SunTrust Banks began coverage on shares of Summit Therapeutics in a research note on Thursday, January 4th. They issued a “buy” rating and a $24.00 price objective on the stock. ValuEngine cut shares of Summit Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, October 5th. Finally, Oppenheimer reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Summit Therapeutics in a research note on Monday, October 16th. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $21.20.
Summit Therapeutics Company Profile
Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.